Latanoprost Pensa Pharma

Latanoprost, the active ingredient in Latanoprost Pensa Pharma, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Pensa Pharma as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and serving hospitals, pharmacies and clinics worldwide. The company provides reliable cold‑chain logistics where required and supports regulatory documentation for import, and timely delivery.

Latanoprost is a prostaglandin analog that reduces intraocular pressure by enhancing uveoscleral outflow, and it is indicated for the following ocular conditions.

Primary open-angle glaucoma: lowers intraocular pressure to slow disease progression and preserve visual field. Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma. Secondary open-angle glaucoma: decreases intraocular pressure when other causes are present. Pseudoexfoliative glaucoma: helps control pressure in this specific subtype. Normal-tension glaucoma: provides pressure reduction to protect the optic nerve.

Latanoprost may cause ocular and systemic adverse reactions; most are mild and reversible.

Common Side Effects: - Eye redness or hyperemia - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Increased eyelash length and thickness - Darkening of the iris color - Periocular skin hyperpigmentation

Serious or Rare Side Effects: - Uveitis or severe eye inflammation - Allergic reactions such as contact dermatitis - Corneal edema or keratitis - Vision loss or sudden visual acuity decline - Ocular infection secondary to contamination - Systemic hypersensitivity reactions

Before initiating therapy, clinicians should evaluate ocular health and consider patient‑specific factors. - Assess baseline intraocular pressure: ensure accurate measurement prior to treatment. - Monitor iris color changes: inform patients that permanent darkening may occur. - Evaluate for history of ocular inflammation: avoid use in active uveitis. - Avoid use in patients with active ocular infection: infection may worsen. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, potentially altering efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogs: may cause excessive intraocular pressure reduction. - Use with non‑steroidal anti‑inflammatory eye drops: can diminish latanoprost’s pressure‑lowering effect. - Administration with contact lenses: may affect drug absorption and cause irritation.

Moderate Interactions (Monitor Closely): - Systemic beta‑blockers: combined effect on intraocular pressure may require monitoring. - Systemic corticosteroids: may counteract latanoprost’s action, necessitating pressure checks. - Antihistamine eye drops: may increase risk of ocular surface discomfort.